Información de Alkermes Plc, dividendo de Alkermes Plc, actividades de los accionistas y más

Más Datos de Alkermes Plc Compañía

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Información de Alkermes Plc



Símbolo de cotizaciónALKS

Nombre de la empresaAlkermes Plc

Fecha de salida a bolsaJul 16, 1991

Director ejecutivoPops (Richard F)

Número de empleados1800

Tipo de seguridadOrdinary Share

Fin del año fiscalJul 16

DirecciónConnaught House

CiudadDUBLIN

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísIreland

Código postalD04 C5Y6

Teléfono35317728000

Sitio Webhttps://www.alkermes.com/

Símbolo de cotizaciónALKS

Fecha de salida a bolsaJul 16, 1991

Director ejecutivoPops (Richard F)

Ejecutivos de Alkermes Plc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.38M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

231.56K

-0.88%

Mr. Shane M. Cooke

Independent Director

103.74K

--

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

81.39K

-4.91%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

--

Dr. Cato T. Laurencin, M.D., Ph.D.

Independent Director

29.10K

--

Dr. Christopher I. Wright, M.D., Ph.D.

Independent Director

23.01K

--

Ms. Nancy S. Lurker

Independent Director

13.55K

+21.03%

Dr. Nancy L. Snyderman, M.D.

Independent Director

--

Mr. C. Todd Nichols

Senior Vice President, Chief Commercial Officer

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.38M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

231.56K

-0.88%

Mr. Shane M. Cooke

Independent Director

103.74K

--

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

81.39K

-4.91%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

--

Dr. Cato T. Laurencin, M.D., Ph.D.

Independent Director

29.10K

--

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de abr

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

VIVITROL

467.91M

31.70%

ARISTADA

370.04M

25.07%

LYBALVI

346.69M

23.49%

Royalty Revenue - VUMERITY

113.93M

7.72%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

109.57M

7.42%

Otro

67.75M

4.59%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

1.37B

93.01%

Rest of the World

102.36M

6.94%

Ireland

754.00K

0.05%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

VIVITROL

467.91M

31.70%

ARISTADA

370.04M

25.07%

LYBALVI

346.69M

23.49%

Royalty Revenue - VUMERITY

113.93M

7.72%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

109.57M

7.42%

Otro

67.75M

4.59%

Estadísticas de accionistas

Actualizado: jue., 7 de may

Accionistas

Tipos de accionistas

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

14.44%

Baker Bros. Advisors LP

6.01%

Vanguard Portfolio Management, LLC

5.71%

State Street Investment Management (US)

5.68%

T. Rowe Price Associates, Inc.

5.28%

Otro

62.88%

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

14.44%

Baker Bros. Advisors LP

6.01%

Vanguard Portfolio Management, LLC

5.71%

State Street Investment Management (US)

5.68%

T. Rowe Price Associates, Inc.

5.28%

Otro

62.88%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

53.52%

Investment Advisor/Hedge Fund

29.75%

Hedge Fund

19.22%

Research Firm

2.49%

Pension Fund

2.14%

Individual Investor

1.41%

Sovereign Wealth Fund

1.17%

Bank and Trust

0.48%

Private Equity

0.42%

Participación institucional



Actualizado: mié., 1 de abr

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2026Q1

783

182.39M

109.43%

-12.00M

2025Q4

744

175.23M

117.54%

-23.12K

2025Q3

767

175.30M

122.16%

+2.11M

2025Q2

769

173.38M

125.62%

-4.15M

2025Q1

759

177.46M

124.05%

-27.05M

2024Q4

734

172.08M

130.58%

-12.03M

2024Q3

705

184.36M

134.23%

-884.11K

2024Q2

687

185.17M

126.42%

+3.87M

2024Q1

659

181.61M

124.10%

-28.36M

2023Q4

633

182.01M

111.83%

+12.84M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

BlackRock Institutional Trust Company, N.A.

24.07M

14.44%

+417.41K

+1.76%

Dec 31, 2025

Baker Bros. Advisors LP

10.01M

6.01%

+1.92M

+23.74%

Dec 31, 2025

State Street Investment Management (US)

9.47M

5.68%

+932.51K

+10.92%

Dec 31, 2025

T. Rowe Price Associates, Inc.

8.80M

5.28%

-1.25M

-12.41%

Dec 31, 2025

Renaissance Technologies LLC

6.67M

4%

+375.50K

+5.97%

Dec 31, 2025

American Century Investment Management, Inc.

5.96M

3.57%

+1.56M

+35.46%

Dec 31, 2025

JP Morgan Asset Management

4.83M

2.9%

+1.21M

+33.37%

Dec 31, 2025

Dimensional Fund Advisors, L.P.

4.41M

2.65%

+714.79K

+19.33%

Dec 31, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

AdvisorShares Psychedelics ETF

7.31%

iShares Neuroscience and Healthcare ETF

3.82%

First Trust NYSE Arca Biotechnology Index Fund

3.3%

Invesco S&P SmallCap Health Care ETF

3.1%

ALPS Medical Breakthroughs ETF

2.07%

Knowledge Leaders Developed World ETF

1.69%

Langar Global HealthTech ETF

1.44%

State Street SPDR S&P Biotech ETF

1.35%

Abacus FCF International Leaders ETF

1.34%

Invesco S&P SmallCap Quality ETF

1.32%

AdvisorShares Psychedelics ETF

Proporción7.31%

iShares Neuroscience and Healthcare ETF

Proporción3.82%

First Trust NYSE Arca Biotechnology Index Fund

Proporción3.3%

Invesco S&P SmallCap Health Care ETF

Proporción3.1%

ALPS Medical Breakthroughs ETF

Proporción2.07%

Knowledge Leaders Developed World ETF

Proporción1.69%

Langar Global HealthTech ETF

Proporción1.44%

State Street SPDR S&P Biotech ETF

Proporción1.35%

Abacus FCF International Leaders ETF

Proporción1.34%

Invesco S&P SmallCap Quality ETF

Proporción1.32%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos